MX2022003744A - Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas. - Google Patents

Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas.

Info

Publication number
MX2022003744A
MX2022003744A MX2022003744A MX2022003744A MX2022003744A MX 2022003744 A MX2022003744 A MX 2022003744A MX 2022003744 A MX2022003744 A MX 2022003744A MX 2022003744 A MX2022003744 A MX 2022003744A MX 2022003744 A MX2022003744 A MX 2022003744A
Authority
MX
Mexico
Prior art keywords
domain variants
domain
light chain
same
multispecific antibodies
Prior art date
Application number
MX2022003744A
Other languages
English (en)
Inventor
Eric Krauland
Paul Widboom
Kevin Schutz
Arvind Sivasubramanian
Michaela Helble
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of MX2022003744A publication Critical patent/MX2022003744A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N19/00—Methods or arrangements for coding, decoding, compressing or decompressing digital video signals
    • H04N19/10—Methods or arrangements for coding, decoding, compressing or decompressing digital video signals using adaptive coding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Signal Processing (AREA)
  • Multimedia (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan variantes del dominio CH1 modificadas genéticamente para la unión preferencial a un dominio CL kappa o un dominio CL lambda, así como también polipéptidos, por ejemplo, cadenas pesadas de anticuerpos o anticuerpos, que comprenden dichas variantes del dominio CH1 modificadas genéticamente, y composiciones farmacéuticas que comprenden dichas variantes del dominio CH1 y/o dichos polipéptidos, y métodos para fabricar y usar dichas variantes del dominio CH1. Las variantes del dominio CH1 minimizan el emparejamiento incorrecto de cadena pesada-cadena ligera y promueven el emparejamiento de cadena pesada-cadena ligera afín, lo que mejora de esta manera la generación de anticuerpos multiespecíficos, por ejemplo, biespecíficos. También se proporcionan métodos para fabricar bibliotecas de variantes del dominio CH1 y métodos para identificar una o más variantes del dominio CH1.
MX2022003744A 2019-09-30 2020-09-30 Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas. MX2022003744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962908367P 2019-09-30 2019-09-30
PCT/US2020/053482 WO2021067404A2 (en) 2019-09-30 2020-09-30 Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same

Publications (1)

Publication Number Publication Date
MX2022003744A true MX2022003744A (es) 2022-07-21

Family

ID=75338609

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003744A MX2022003744A (es) 2019-09-30 2020-09-30 Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas.

Country Status (11)

Country Link
US (1) US20230265134A1 (es)
EP (1) EP4021939A4 (es)
JP (1) JP2022550172A (es)
KR (1) KR20220107163A (es)
CN (1) CN114846027A (es)
AU (1) AU2020357944A1 (es)
BR (1) BR112022005995A2 (es)
CA (1) CA3152460A1 (es)
IL (1) IL291728A (es)
MX (1) MX2022003744A (es)
WO (1) WO2021067404A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
JP2024530402A (ja) * 2021-07-12 2024-08-21 ジェネンテック， インコーポレイテッド 抗体－リパーゼ結合を減少させるための構造
WO2023079101A2 (en) * 2021-11-05 2023-05-11 Alligator Bioscience Ab Novel polypeptides
AU2023232876A1 (en) * 2022-03-11 2024-10-03 Elpiscience (Suzhou) Biopharma, Ltd. Modified antibodies and uses thereof
WO2024061223A1 (zh) * 2022-09-20 2024-03-28 普米斯生物技术(珠海)有限公司 抗体及其在抗肿瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
KR20150143458A (ko) * 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
EP2966085A1 (en) * 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
AU2016252773B2 (en) * 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
SG11201900373WA (en) * 2016-07-19 2019-02-27 Ibentrus Inc Bispecific proteins and methods for preparing same

Also Published As

Publication number Publication date
EP4021939A2 (en) 2022-07-06
CN114846027A (zh) 2022-08-02
JP2022550172A (ja) 2022-11-30
EP4021939A4 (en) 2023-11-22
US20230265134A1 (en) 2023-08-24
IL291728A (en) 2022-05-01
WO2021067404A2 (en) 2021-04-08
BR112022005995A2 (pt) 2022-06-21
CA3152460A1 (en) 2021-04-08
KR20220107163A (ko) 2022-08-02
AU2020357944A1 (en) 2022-03-31
WO2021067404A3 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
MX2022003744A (es) Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas.
MA49034B1 (fr) Anticorps anti-lag3
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
MX2024000317A (es) Anticuerpos biespecificos contra calicreina y factor xii del plasma.
GB2468232A (en) Antigen-bindng constructs
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX2012003598A (es) Anticuerpos biespecificos agonistas de receptores de muerte.
CA2808482C (en) Methods for the generation of multispecific and multivalent antibodies
AU2010234031A8 (en) Trivalent, bispecific antibodies
JOP20210304A1 (ar) علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
NO20084878L (no) Humanisert C-kit antistoff
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
NZ740474A (en) Antigen receptors and uses thereof
ECSP099692A (es) Ligandos de receptor de vainilloide novedosos y su uso de los mismos para la produccion de sustancias farmaceuticas
MX2021012871A (es) Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
ZA202201796B (en) Tetravalent symmetric bispecific antibody
WO2016100533A3 (en) Intercalated single-chain variable fragments